Research programme: small molecule protein inhibitors - Cypralis

Drug Profile

Research programme: small molecule protein inhibitors - Cypralis

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Cypralis Limited
  • Developer Cypralis Limited; Selcia; University of Liverpool
  • Class Small molecules
  • Mechanism of Action Cyclophilin D inhibitors; Cyclophilin inhibitors; Peptidylprolyl isomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammation; Pancreatitis; Wounds

Most Recent Events

  • 23 Jan 2017 Early research in Pancreatitis in United Kingdom (unspecified route) before January 2017
  • 23 Jan 2017 Cypralis plans to submit Clinical Trial Application (CTA) for Pancreatitis in United Kingdom
  • 15 Jul 2016 Early research in Inflammation in United Kingdom (unspecified route) (Cypralis pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top